相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart
Giovanni Adami et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Dolores Shoback et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk
Jeffrey R. Curtis et al.
MEDICAL CARE (2020)
FRAX: re-adjust or re-think
Yasser El Miedany
ARCHIVES OF OSTEOPOROSIS (2020)
Economic Burden of Osteoporotic Fractures in US Managed Care Enrollees
Setareh A. Williams et al.
AMERICAN JOURNAL OF MANAGED CARE (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults
Donna M. Fick et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention A Systematic Review
Howard A. Fink et al.
ANNALS OF INTERNAL MEDICINE (2019)
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review
F. Fatoye et al.
BMJ OPEN (2019)
Associations between health-related quality of life, physical function and pain in older women with osteoporosis and vertebral fracture
Brita Stanghelle et al.
BMC GERIATRICS (2019)
Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study
Stefano Gonnelli et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2019)
How to perform a meta-analysis with R: a practical tutorial
Sara Balduzzi et al.
EVIDENCE-BASED MENTAL HEALTH (2019)
Risk factors for medication-related osteonecrosis of the jaws: A systematic review
K. McGowan et al.
ORAL DISEASES (2018)
An assessment of the relation between bone mineral density and clinic-demographic properties and life quality during postmenopausal period
Omur Aktas et al.
JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION (2018)
How Can We Improve Osteoporosis Care? A Systematic Review and Meta-Analysis of the Efficacy of Quality Improvement Strategies for Osteoporosis
Smita Nayak et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study
Annette L. Adams et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density
K. E. Naylor et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Quality of life and psychological consequences in elderly patients after a hip fracture: a review
Konstantinos I. Alexiou et al.
CLINICAL INTERVENTIONS IN AGING (2018)
Risk factors and quality of life for the occurrence of hip fracture in postmenopausal women
Fang-Ping Chen et al.
BIOMEDICAL JOURNAL (2018)
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
Panagiotis Anagnostis et al.
MATURITAS (2017)
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
M. A. Mignot et al.
OSTEOPOROSIS INTERNATIONAL (2017)
An overview and management of osteoporosis
Tumay Sozen et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2017)
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO)
Jun Iwamoto et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2016)
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday
L. H. R. Xu et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Robert A. Adler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
The association between bone mineral density, quality of life, quality of sleep and fatigue
Ilknur Albayrak et al.
ACTA CLINICA BELGICA (2016)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
Brian Louis McNabb et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Patient Characteristics Associated with Medication Adherence
Sharon Rolnick et al.
CLINICAL MEDICINE & RESEARCH (2013)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Development of the RTI item bank on risk of bias and precision of observational studies
Meera Viswanathan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Laura Y. Park-Wyllie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Kurt A. Kennel et al.
MAYO CLINIC PROCEEDINGS (2009)
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday
J. R. Curtis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
KE Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
分享论文
